Colman the Mayne man for 2004
29 November, 2004 by Graeme O'NeillThe awards keep coming for X-ray crystallographer Prof Peter Colman, whose 3D elucidation of the influenza virus's neuraminidase enzyme in the 1980s helped build a firewall against the most dangerous virus on the planet.
Cytopia drug shepherded into Cancer Research UK program
23 November, 2004 by Graeme O'NeillMelbourne drug-discovery biotech Cytopia has made it onto the dance card of the world's largest volunteer-supported cancer research organisation, Cancer Research UK after the UK agency agreed to take Cytopia's promising anti-cancer drug CYT997 into its clinical trial program.
WEHI, Iliad to collaborate on MS project
19 November, 2004 by Melissa TrudingerMelbourne drug development company Iliad Chemicals will collaborate with scientists at the Walter and Eliza Hall Institute (WEHI) on the development of a new class of compounds with the potential to treat multiple sclerosis.
Therapeutic promise in prize winner's work
18 November, 2004 by Susan WilliamsonLevon Khachigian, an associate professor at the University of NSW, has been awarded the 2004 Australasian Science prize for his team's work on developing potential therapeutics for vascular diseases, such as artherosclerosis, and cancer.
Molecule may be key to spinal cord regeneration
18 November, 2004 by Melissa TrudingerResearchers at the Queensland Brain Institute and the University of Melbourne have identified a molecule which they believe may play a crucial role in preventing spinal cord regeneration.
Avexa in HIV therapy partnership
15 November, 2004 by Graeme O'NeillInfectious disease drug-developer Avexa (ASX:AVX) is to work with researchers at the University of Leuven's Rega Institute in Belgium to develop a new HIV/AIDS therapy that will block the virus' integrase enzyme.
NHMRC grants lure eminent immunologist home
12 November, 2004 by Melissa TrudingerExpatriate Australian immunologist Prof Jonathan Sprent will return to Australia next year from the Scripps Research Institute in San Diego, California, to take up a position at Sydney's Centenary Institute after being awarded a prestigious Burnet Award from the National Health and Medical Research Council (NHMRC).
Biotron publishes SARS research
11 November, 2004 by Melissa TrudingerCanberra biotech company Biotron (ASX:BIT) has published the results of its SARS virus ion channel research in the journal Virology.
Sydney team joins global paediatric cancer fight
05 November, 2004 by Melissa TrudingerSydney's Children's Cancer Institute Australia (CCIA) has joined leading paediatric cancer institutes in the US including St Jude Children's Research Hospital, Children's Hospital of Los Angeles, Children's Hospital of Philadelphia, Duke University Medical Centre, and Memorial Sloan- Kettering Cancer Centre to test new cancer drugs for the treatment of childhood cancers.
Novogen soars as subsidiary hits the fast track
05 November, 2004 by Renate KrelleInvestors added more than AUD$1 -- or 20 per cent -- to Novogen's (ASX:NRT) share price today on the news that the company's subsidiary Marshall Edwards (Nasdaq: MSHL/LSE AIM:MSH) had been granted fast-track status for the use of phenoxodiol in recurrent ovarian cancer.
Mouse model may provide link between metabolism, disease
04 November, 2004 by Graeme O'NeillA gene called c-Cbl ('see sybil') has emerged as a hot -- literally -- new lead into the genetic maze linking differences in energy metabolism to obesity and type 2 diabetes.
NZ's Neuren eyes Australian capital markets
01 November, 2004 by Melissa TrudingerNew Zealand biotechnology company Neuren Pharmaceuticals is evaluating possible options in Australia for raising capital, including private equity and an IPO on the ASX.
Prima secures $10m and institutional support
27 October, 2004 by Melissa TrudingerPrima Biomed (ASX: PRR) announced today it had finalised its $10 million placement to institutional and sophisticated investors.
Qld team hits new target in fat research
27 October, 2004 by Graeme O'NeillA research team at the University of Queensland has identified a promising new target for an anti-obesity therapy: an enzyme that appears to have a central role in the development of fat-storage cells called adipocytes.
Onyx falls behind in cancer drug race
26 October, 2004 by Staff WritersOnyx Pharmaceuticals - which is developing one of the most promising new cancer therapies on the horizon - has said it will not file for US approval of its kidney cancer drug as soon as some investors had anticipated.
